Showing 1 - 9 of 9    

Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)

This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral...

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used as part of combination anti...

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

The main purpose of this study is to find out how stimulant medications (methylphenidate or amphetam...

IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission

IMPAACT P1115 will explore the effects of early intensive antiretroviral therapy (ART) on achieving...

PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children (PBPK)

Developmental changes in physiology during childhood influence drug dosing. Failure to account for t...

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection

This study will evaluate the safety and pharmacokinetics (PKs) of raltegravir (RAL) given to HIV-1-e...

Safety of and Immune Response to Dolutegravir (GSK1349572) in HIV-1 Infected Infants, Children, and Adolescents

Dolutegravir (DTG) (also known as GSK1349572) is a new drug that may slow HIV replication. It works...

Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women

SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero expos...

Showing 1 - 9 of 9